Department of Oral Health Sciences, University of Washington, Seattle, United States; Department of Pathology, University of Washington, Seattle, United States
Department of Oral Health Sciences, University of Washington, Seattle, United States; Center of Excellence in Maternal and Child Health, University of Washington, Seattle, United States
Department of Oral Health Sciences, University of Washington, Seattle, United States; Department of Periodontics, University of Washington, Seattle, United States
Timothy C Cox
Department of Pediatrics, University of Washington, Seattle Children’s Research Institute, Seattle, United States
Department of Oral Health Sciences, University of Washington, Seattle, United States; Department of Pathology, University of Washington, Seattle, United States
Periodontal disease is an age-associated disorder clinically defined by periodontal bone loss, inflammation of the specialized tissues that surround and support the tooth, and microbiome dysbiosis. Currently, there is no therapy for reversing periodontal disease, and treatment is generally restricted to preventive measures or tooth extraction. The FDA-approved drug rapamycin slows aging and extends lifespan in multiple organisms, including mice. Here, we demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mice, including regeneration of periodontal bone, attenuation of gingival and periodontal bone inflammation, and revertive shift of the oral microbiome toward a more youthful composition. This provides a geroscience strategy to potentially rejuvenate oral health and reverse periodontal disease in the elderly.
